Pharmacogenomics of central nervous system (CNS) drugs

Drug Development Research

Volumn 73, Issue 8, 2012, Pages 461-476

  Cacabelos, Ramón ^a  

^a Centro de Investigacion Biomedica EuroEspes   (Spain)

Author keywords

Alzheimer's disease; APOE; CNS disorders; CYP2C19; CYP2C9; CYP2D6; CYP3A4 5; pharmacogenomics; psychotropic drugs; transporters

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ARIPIPRAZOLE; BENPERIDOL; BROMPERIDOL; CENTRAL NERVOUS SYSTEM AGENTS; CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; MOLINDONE; OLANZAPINE; PALIPERIDONE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; PIPOTIAZINE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; UNINDEXED DRUG; ZIPRASIDONE; ZUCLOPENTHIXOL;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME 1; CHROMOSOME 10; CHROMOSOME 11; CHROMOSOME 17; CHROMOSOME 19; CHROMOSOME 6; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSPORT; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HEREDITY; HUMAN; PATHOGENESIS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; X CHROMOSOME;

EID: 84870916886     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21039     Document Type: Review

References (41)

1. Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK,. 2003. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 67: 657-685.
2. Alzgene.org. Alzheimer Research Forum. 2012. http://www.alzgene.org. Accessed 1 June 2012.
3. Anderson CNG, Grant SGN,. 2006. High throughput protein expression screening in the nervous system-needs and limitations. J Physiol 575: 367-372.
4. Boudreau RL, Spengler RM, Davidson BL,. 2011. Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol Ther 19: 2169-2177.
5. Cacabelos R,. 2005. Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Exp Opin Pharmacother 6: 1967-1987.
6. Cacabelos R,. 2007a. Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease. Mol Diag Ther 11: 385-405.
7. Cacabelos R,. 2007b. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression. Meth Find Exper Clin Pharmacol 29 (Suppl B): 1-91.
8. Cacabelos R,. 2008a. Pharmacogenomics and therapeutic prospects in dementia. Eur Arch Psychiatry Clin Neurosci 258 (Suppl 1): 28-47.
9. Cacabelos R,. 2008b. Pharmacogenomics in Alzheimer's disease. Meth Mol Biol 448: 213-357.
10. Cacabelos R,. 2009a. The path to personalized medicine in mental disorders. In:, Ritsner MS, editor. The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes. 4). Berlin: Springer, p 3-63.
11. Cacabelos R,. 2009b. Pharmacogenomics and therapeutic strategies for dementia. Expert Rev Mol Diagn 9: 567-611.
12. Cacabelos R, editor. 2012. World Guide for Drug Use and Pharmacogenomics. Corunna: EuroEspes Publishing. (in press)
13. Cacabelos R, Fernández-Novoa L, Lombardi V, Kubota Y, Takeda M,. 2005. Molecular genetics of Alzheimer's disease and aging. Meth Find Exper Clin Pharmacol 27 (Suppl A): 1-573.
14. Cacabelos R, Fernández-Novoa L, Martínez-Bouza R, McKay A, Carril JC, Lombardi V, Corzo L, Carrera I, Tellado I, Nebril L, et al. 2010. Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. Pharmaceuticals 3: 3040-3100.doi: 10.3390/ph3103040.
15. Cacabelos R, Martínez R, Fernández-Novoa L, Carril JC, Lombardi V, Carrera I, Corzo L, Tellado I, Leszek J, McKay A, et al. 2012a. Genomics of dementia: APOE- and CYP2D6-related pharmacogenetics. Int J Alzheimer Dis. doi: 10.1155/2012/518901.
16. Cacabelos R, Martínez-Bouza R,. 2010. Genomics and pharmacogenomics of schizophrenia. CNS Neuroscience & Therapeutics 17: 541-565.
17. Cacabelos R, Martínez-Bouza R, Carril JC, Fernández-Novoa L, Lombardi V, Carrera I, Corzo L, McKay A,. 2012b. Genomics and pharmacogenomics of brain disorders. Cur Pharm Biotech 13: 674-725.
18. Carl SM, Lindley DJ, Couraud PO, Weksler BB, Romero I, Mowery SA, Knipp GT,. 2010. ANC and SLC transporter expression and Pot substrate characterization across the human CMEC/D3 blood-brain barrier cell line. Mol Pharm 7: 1057-1068.
19. Gonzalez-Alegre P,. 2007. Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. Pharmacol Ther 114: 34-55.
20. Hardy J, Selkoe DJ,. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
21. Haufroid V,. 2011. Genetic Polymorphisms of ATP-Binding Cassette Transporters ABCB1 and ABCC2 and their Impact on Drug Disposition. Curr Drug Targets 12: 631-646.
22. Hosoya K, Tachikawa M,. 2011. Roles of organic anion/cation transporters at the blood-brain and blood-cerebrospinal fluid barriers involving uremic toxins. Clin Exp Nephrol 15: 478-485.
23. Ingelman-Sundberg M, Sim SC, Gomez A, Rodríguez-Antona C,. 2007. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116: 496-526.
24. Isaza CA, Henao J, López AM, Cacabelos R,. 2000. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Meth Find Exp Clin Pharmacol 22: 695-705.
25. Ishikawa T, Onishi Y, Hirano H, Oosumi K, Nagakura M, Tarui S,. 2004. Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Biol Pharm Bull 27: 939-948.
26. Johnson AD, Wang S, Sadee W,. 2005. Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics. Pharmacol Ther 106: 19-38.
27. Leung RK, Whittaker PA,. 2005. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 107: 222-239.
28. Malhotra AK, Lencz T, Correll CU, Kane JM,. 2007. Genomics and the future of pharmacotherapy in psychiatry. Int Rev Psychiatry 19: 523-530.
29. Marquez B, Van Bambeke F,. 2011. ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions. Curr Drug Targets 12: 600-620.
30. Mizutani T,. 2003. 2003. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 35: 99-106.
31. NCBI. 2012. National Center for Biotechnology Information. http://www.ncbi.nlm.nih.gov/omim. Accessed 1 June 2012.
32. Need AC, Motulsky AG, Goldstein DB,. 2005. Priorities and standards in pharmacogenetic research. Nat Genet 37: 671-681.
33. Nishimura M, Naito S,. 2008. Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. Drug Metab Pharmacokinet 23: 22-44.
34. Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, Sawada J,. 2004. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 19: 83-95.
35. Selkoe DJ, Podlisny MB,. 2002. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 3: 67-99.
36. Suh YH, Checler F,. 2002. Amyloid precursor protein, presenilins, and α synuclein: Molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev 54: 469-525.
37. Weinshilboum RM, Wang L,. 2006. Pharmacogenetics and pharmacogenomics: Development, science, and translation. Annu Rev Genomics Hum Genet 7: 223-245.
38. Xie HG, Kim RB, Wood AJ, Stein CM,. 2001. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharm Toxicol 41: 815-850.
39. Xu X, Zhan M, Duan W, Prabhu V, Brenneman R, Wood W, Firman J, Li H, Zhang P, Ibe C, et al. 2007. Gene expression atlas of the mouse central nervous system: impact and interactions of age, energy intake and gender. Genome Biol 8: R234.
40. Ying SY, Lin SL,. 2009. Intron-mediated RNA interference and microRNA biogenesis. Methods Mol Biol 487: 387-413.
41. Zhou SF, Di YM, Chan E, Du YM, Chow VD, Xue CC, Lai X, Wang JC, Li CG, Tian M, et al. 2008. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 9: 738-784.